EP1069901A1 - Composes calcilytiques et leur utilisation - Google Patents

Composes calcilytiques et leur utilisation

Info

Publication number
EP1069901A1
EP1069901A1 EP99917374A EP99917374A EP1069901A1 EP 1069901 A1 EP1069901 A1 EP 1069901A1 EP 99917374 A EP99917374 A EP 99917374A EP 99917374 A EP99917374 A EP 99917374A EP 1069901 A1 EP1069901 A1 EP 1069901A1
Authority
EP
European Patent Office
Prior art keywords
group
alkyl
chloro
hydroxy
dimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99917374A
Other languages
German (de)
English (en)
Other versions
EP1069901A4 (fr
Inventor
Pradip Kumar Bhatnagar
James Francis Callahan
Eric G. Del Mar
Maria Amparo Lago
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire NPS Pharmaceuticals Inc
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
NPS Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp, NPS Pharmaceuticals Inc filed Critical SmithKline Beecham Corp
Publication of EP1069901A1 publication Critical patent/EP1069901A1/fr
Publication of EP1069901A4 publication Critical patent/EP1069901A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals

Definitions

  • the present invention relates to novel calciiytic compounds, pharmaceutical compositions containing these compounds and their use as calcium receptor antagonists.
  • extracellular Ca ⁇ + In mammals, extracellular Ca ⁇ + is under rigid homeostatic control and regulates various processes such as blood clotting, nerve and muscle excitability, and proper bone formation.
  • Extracellular Ca ⁇ + inhibits the secretion of parathyroid hormone ("PTH") from parathyroid cells, inhibits bone resorption by osteoclasts, and stimulates secretion of calcitonin from C-cells.
  • PTH parathyroid hormone
  • Calcium receptor proteins enable certain specialized cells to respond to changes in extracellular Ca ⁇ + concentration.
  • PTH is the principal endocrine factor regulating Ca ⁇ + homeostasis in the blood and extracellular fluids.
  • PTH by acting on bone and kidney cells, increases the level of Ca ⁇ + in the blood. This increase in extracellular Ca ⁇ + then acts as a negative feedback signal, depressing PTH secretion.
  • Extracellular Ca ⁇ + acts directly on parathyroid cells to regulate PTH secretion. The existence of a parathyroid cell surface protein which detects
  • this protein acts as a calcium receptor
  • extracellular Ca2+ plays a role in parafollicular (C-cells) and parathyroid cells. See Nemeth, Cell Calcium 11:323, 1990.
  • the role of extracellular Ca ⁇ + on bone osteoclasts has also been studied. See Zaidi, Bioscience Reports 10:493, 1990.
  • Calcilytics are compounds able to inhibit calcium receptor activity, thereby causing a decrease in one or more calcium receptor activities evoked by extracellular Ca + .
  • Calcilytics are useful as lead molecules in the discovery, development, design, modification and/or construction of useful calcium modulators which are active at Ca + receptors.
  • Such calcilytics are useful in the treatment of various disease states characterized by abnormal levels of one or more components, e.g., polypeptides such as hormones, enzymes or growth factors, the expression and/or secretion of which is regulated or affected by activity at one or more Ca + receptors.
  • Target diseases or disorders for calcilytic compounds include diseases involving abnormal bone and mineral homeostasis.
  • Abnormal calcium homeostasis is characterized by one or more of the following activities: an abnormal increase or decrease in serum calcium; an abnormal increase or decrease in urinary excretion of calcium; an abnormal increase or decrease in bone calcium levels (for example, as assessed by bone mineral density measurements); an abnormal absorption of dietary calcium; an abnormal increase or decrease in the production and/or release of messengers which affect serum calcium levels such as PTH and calcitonin; and an abnormal change in the response elicited by messengers which affect serum calcium levels.
  • calcium receptor antagonists offer a unique approach towards the pharmacotherapy of diseases associated with abnormal bone or mineral homeostasis, such as hypoparathyroidism, osteosarcoma, periodontal disease, fracture healing, osteoarthritis, rheumatoid arthritis, Paget's disease, humoral hypercalce ia associated with malignancy and fracture healing, and osteoporosis.
  • the present invention comprises novel calcium receptor antagonists represented by Formula (I) hereinbelow and their us in the treatment of a variety of diseases associated with abnormal bone or mineral homeostasis, including but not limited to hypoparathyroidism, osteosarcoma, periodontal disease, fracture healing, osteoarthritis, rheumatoid arthritis, Paget's disease, humoral hypercalcemia associated with malignancy and fracture healing, and osteoporosis.
  • diseases associated with abnormal bone or mineral homeostasis including but not limited to hypoparathyroidism, osteosarcoma, periodontal disease, fracture healing, osteoarthritis, rheumatoid arthritis, Paget's disease, humoral hypercalcemia associated with malignancy and fracture healing, and osteoporosis.
  • the present invention further provides a method for antagonizing calcium receptors in an animal, including humans, which comprises administering to an animal in need thereof an effective amount of a compound of Formula (I), indicated hereinbelow.
  • the present invention further provides a method for increasing serum parathyroid levels in an animal, including humans, which comprises administering to an animal in need thereof an effective amount of a compound of Formula (I), indicated hereinbelow.
  • Y is a covalent bond, alkylene or alkenylene of up to 4 carbon atoms, unsubstituted or substituted by C 1.4 alkyl or O;
  • Y2 is methylene, unsubstituted or substituted by C 1.4 alkyl or haloalkyl
  • Y3 is covalent bond or O, S, N-R ⁇ or C1.4 alkylene-O, C j _4 alkylene-S, C1.4 alkylene-N-R ⁇ V ;
  • R ⁇ is selected from the group consisting of H, Cj_4 alkyl, C3.6 cycloalkyl;
  • R3 and R4 are, independently, methyl or ethyl, or, together, form cyclopropyl
  • R5 is heteroaryl or fused heteroaryl; wherein the hetero-ring contains N, O or S, and is aromatic, dihydro or tetrahydro, unsubstituted or substituted with any substituents being selected from the group consisting of OH, OCH3, CH(CH3)2, halogen, C ⁇ _4 alkyl, Cj_4 alkoxy, C 3 . 6 cycloalkyl, OS0 2 R IV , CN, N0 2 , OCF3,
  • n is an integer from 0 to 3;
  • G is a covalent bond, CHRg or C-Rg ,wherein Rg is H, OH or O (forming a ketone); R 7 is H, OH, or 0-C ⁇ _4 alkyl;
  • Rg is H or C ⁇ _4 alkyl; or R7 and Rg together form a ketone;
  • a and B are, independently, selected from the group consisting of a bond, CH2,
  • X is selected from sub formulas (la) to (Ie) hereinbelow:
  • W is selected from the group consisting of Ri , SO2R1, C(0)R ⁇ , SO2NR1R1 , C(0)NR ⁇ R ⁇ ', C(0)OR ⁇ , SO3R1', wherein R ⁇ and Ri 'are independently selected from the group consisting of hydrogen, Cj_4 alkyl, C3.6 cycloalkyl, C2.5 alkenyl, C2.5 alkynyl, heterocycloalkyl, aryl and aryl C1.4 alkyl; or R ⁇ and Ri together form a 3 to 7 membered optionally substituted heterocyclic ring; wherein any substituents are selected from the group consisting of CN, aryl, CO2R, CO2NHR, OH, OR, NH2, halo, CF3, OCF3 and N0 2 ; wherein R represents C ⁇ _4 alkyl, or C3.
  • Xi is selected from the group consisting of CN, NO2, Cl, F, Br, I, H, R ⁇ OR', CF3, OCF3 and OSO2R', wherein R' represents C ⁇ _4 alkyl, or C3.6 cycloalkyl;
  • X2 , X3 and X4 are, independently, selected from the group consisting of CN, N0 2 , Cl, F, Br, I, H, R", OR", CF 3 , OCF3 and OS0 2 R", provided that either X!
  • X3 is H, wherein R" is C ⁇ 4 alkyl or haloalkyl; or X j and X2 together form an aryl or heteroaryl ring, substituted or unsubstituted; wherein the heteroatom is selected from N, S and O; and any substituents are selected from the group consisting of halo, C ⁇ _4 alkyl, OCF 3 , CF3, OMe, CN, OS0 2 R' and N0 2 ; or X3 and X4 independently represent C(0)R ⁇ ; and
  • R2 is selected from the group consisting of hydrogen, Cj_4 alkyl, C3.6 cycloalkyl, C2-5 alkenyl, C2-5 alkynyl, heterocycloalkyl aryl and aryl-Ci.4 alkyl;
  • X j " is selected from the group consisting of CN, NO2, Cl, F, Br, I, H, R, OR, CF3, OCF3 and OSO2R, wherein R represents C ⁇ alkyl, or C3.6 cycloalkyl;
  • X2", X3" and X4" are, independently, selected from the group consisting of CN, N0 2 , Cl, F, Br, I, H, R ⁇ OR', CF3, OCF3 and OS0 2 R ⁇ provided that either X"!
  • X"3 is H, wherein R' is C 1.4 alkyl or haloalkyl; or Xi ' and X2" together form an aryl or heteroaryl ring, substituted or unsubstituted; wherein the heteroatom is selected from N, S and O and any substituents are selected from the group consisting of halo, Cj_4 alkyl, OCF3, CF3, OMe, CN, OS0 2 -C ⁇ _ 4 alkyl, OSO2- C3-6 cycloalkyl and NO2; or X3" and X4" independently represent C(0)R ⁇ ; and
  • R j " and R2" are, independently, selected from the group consisting of hydrogen, Cj_4 alkyl, C3.6 cycloalkyl, C2.5 alkenyl, C2.5 alkynyl, heterocycloalkyl and aryl; or Rj" and R2" together form a 3 to 7 membered optionally substituted heterocyclic ring; wherein any substituents are selected from the group consisting of CN, aryl, C0 2 R", C0 2 NHR", OH, OR", NH 2 , halo, CF3, OCF3 and N0 2 ; wherein R" represents ⁇ _ ⁇ alkyl, or C3.6 cycloalkyl; X m is selected from the group consisting of CN, NO2, Cl, F, Br, I, H, R, OR, CF3, OCF3 and OSO2R, wherein R represents C ⁇ _4 alkyl, or C3.6 cycloalkyl;
  • X2"', X3"', and X4"' are, independently, selected from the group consisting of CN, N0 2 , Cl, F, Br, I, H, R', OR', CF3, OCF3 and OS0 2 R', provided that either m ⁇ or X"'3 is H, wherein R' is Cj_4 alkyl or haloalkyl; or Xi '" and X2'" together form an aryl or heteroaryl ring, substituted or unsubstituted; wherein the heteroatom is selected from N, S and O and the substituents are selected from the group consisting of halo, C1.4 alkyl, OCF3, CF3,
  • Rj'" and R2" are, independently, selected from the group consisting of hydrogen, C 4 alkyl, C3.6 cycloalkyl, C2.5 alkenyl, C2-5 alkynyl, heterocycloalkyl and aryl; or R ⁇ '"and R2"' together form a 3 to 7 membered optionally substituted heterocyclic ring; wherein the substituents are selected from the group consisting of CN, aryl, C0 2 R", C0 2 NHR", OH, OR", NH 2 , halo, CF 3 , OCF3 and N0 2 ; wherein
  • R" represents C ⁇ _4 alkyl, or C3.6 cycloalkyl
  • D is selected from the group consisting of H, CN, NO2, Cl, F, Br, I, R, OR, SR,
  • R represents C1.4 alkyl, C3.6 cycloalkyl, or C ⁇ _ 10 ar yl or heteroaryl wherein the heteroatom is selected from N, S and O and substituents are selected from the group consisting of halo, C1.4 alkyl, OCF3, CF3,
  • n is the integer 1 or 2; each E is independently C or N, provided that no more than two E moieties are N; further provided that when n is 2, each E is C; a and b are optionally present bonds;
  • Ri ⁇ is selected from the group consisting of (CH2) n C ⁇ 2R ⁇ (CH2) n C ⁇ 2H,
  • R2TM is selected from the group consisting of hydrogen, CN, NO2 Cl, F, Br, I, H,
  • R represents C ⁇ _4 alkyl, or C3.6 cycloalkyl.
  • Y is selected from the group consisting of C, CH, O, N and S; provided that when
  • Y is S, R ⁇ ,v is O or not present; further provided that when Y is O, R ⁇ 1V is not present;
  • X' is selected from the group consisting of CH2, NH, O and S.
  • R9 is selected from the group consisting of O-alkyl, 0-CH2-aryl, and O- aryl;
  • X ⁇ "" is selected from the group consisting of CN, NO2, Cl, F, Br, I, H, R, OR,
  • R represents C1.4 alkyl, or C3.6 cycloalkyl
  • X2'"', X3"", and X4"" are, independently, selected from the group consisting of CN,
  • X""3 is H, wherein R' is C1.4 alkyl or haloalkyl; or X 1 "" and X2"" together form an aryl or heteroaryl ring, substituted or unsubstituted; wherein the heteroatom is selected from N, S and O and the substituents are selected from the group consisting of halo, Ci .4 alkyl, OCF3, CF3,
  • the compounds of the present invention have a structure according to Formula (H):
  • R5 is heteroaryl or fused heteroaryl, wherein the hetero- ring contains N, O or S and is aromatic, dihydro or tetrahydro, unsubstituted or substituted with any substituents being selected from the group consisting of OCH3, halogen, C ⁇ 4 alkyl, , CN, N0 2 , OCF3, CF3, CH 2 CF 3 ; Rg is H; and
  • R5 is heteroaryl or fused heteroaryl, wherein the hetero-ring contains N, O or S and is aromatic, dihydro or tetrahydro, unsubstituted or substituted with any substituents being selected from the group consisting of OCH3, halogen, C ⁇ .4 alkyl, , CN, N0 2 , OCF3, CF 3 , CH 2 CF 3 ;
  • Rg is H; and
  • a and B are, independently, selected from the group consisting of a bond, CH2, 0, or A and B together form a bond.
  • X j is selected from the group consisting of CN, NO2, Cl, F, Br, I and H.
  • X2, X3 and X4 are, independently, selected from the group consisting of Cl, F, Br, I and H, provided X ⁇ and X3 is H.
  • R ⁇ , Rj'and R2 are, independently, selected from the group consisting of C1.4 alkyl, C3.6 cycloalkyl, heterocycloalkyl, aryl or arylalkyl.
  • R ⁇ , Rj'and R2 are, independently, H, alkyl, or aryl. More preferably, X ⁇ is selected from the group consisting of CN, NO2, Cl, F, Br, I and H. More preferably, X2, X3 and X4 are, independently, selected from the group consisting of Cl, F, Br, I and H provided X j and X3 is H. In sub-formula (la), more preferably still, R , Ri 'and R2 are, independently, C . ⁇ alkyl, or aryl. More preferably still, X ⁇ is CN, NO2, or Cl. More preferably still, X2 is Cl, F or H. More preferably still, X3 and X4 are H.
  • X ⁇ is CN, or NO2.
  • X 2 is Cl.
  • Xi " is selected from the group consisting of CN, NO2, Cl, F, Br, I and H.
  • X2", X3" and X4" are, independently, selected from the group consisting of Cl, F, Br, I and H.
  • R ⁇ " and R2" are, independently, selected from the group consisting of C 1.4 alkyl, C3.6 cycloalkyl, heterocycloalkyl or aryl; or Ri “ and R2" together form an optionally substituted 3-7 membered ring, optionally containing an additional heteroatom selected from O, S, and N.
  • Ri " and R2" are, independently, H, C1.4 alkyl, or aryl; or R ⁇ " and R2" together form an optionally substituted 4-7 membered ring, optionally containing a heteroatom selected from O, S, and N. More preferably, Xi " is selected from the group consisting of CN, NO2, Cl, F, Br, I and H. More preferably, X2" is selected from the group consisting of Cl, F, Br, I and H.
  • Ri 'and R2" are, independently, C ⁇ _4 alkyl, or aryl; or R ⁇ " and R2" together form a 4-7 membered ring as described hereinabove. More preferably still, X ⁇ " is CN, NO2, or Cl. More preferably still, X 2 " is Cl, F or H. In sub-formula (Ib), most preferably, R " and R2" together form a 4-7 membered ring as described hereinabove. Most preferably, X ⁇ " is CN, or N ⁇ 2- Most preferably, X2 "is Cl.
  • XiTM is selected from the group consisting of CN, NO2, Cl, F, Br, I and H.
  • X2'", X ⁇ and X4 m are, independently, selected from the group consisting of Cl, F, Br, I and H. provided either X ⁇ "Or X3 m is H.
  • R ⁇ m and R2"' are, independently, selected from the group consisting of Cj_4 alkyl, C3.6 cycloalkyl, heterocycloalkyl or aryl; or R ⁇ m and R2"' together form an optionally substituted 3-7 membered ring, optionally containing an additional heteroatom selected from O, S, and N.
  • R ⁇ m , and R2"' are, independently, H, C j _4 alkyl, or aryl; or Rj"' and R2"' together form an optionally substituted 4-7 membered ring, optionally containing a heteroatom selected from O, S, and N.
  • X ⁇ m is selected from the group consisting of CN, NO2, Cl, F, Br, I and H.
  • X ⁇ , X3TM and X4TM are, independently, selected from the group consisting of Cl, F, Br, I and H provided either X "' or X3"' is H.
  • R ⁇ "'and R2TM are, independently, C ⁇ _4 alkyl, or aryl; or R ⁇ '" and R2"' together form a 4-7 membered ring as described hereinabove.
  • XiTM is CN, NO2, or Cl.
  • X2 " is Cl or H.
  • X3'" and X 4 '" are H.
  • Ri '" and R2'" together form a 4-7 membered ring as described hereinabove.
  • X ⁇ m is CN or NO2.
  • X2 '" is Cl.
  • each D is selected from the group consisting of F, Br, Cl, I, R, OR, SR, and H.
  • R2* v is selected from the group consisting of hydrogen, CN, NO2 Cl, Br, F and I; In sub-formula (Id), more preferably, n is O. More preferably, each E is C.
  • X' is CH2, O, or NH. More preferably, Y is C or N. More preferably, Ri ⁇ v is CH2CO2R', SR', or O forming a ketone.
  • X' is CH2 or O. More preferably still, Ri 1V is CH 2 C0 2 R' or SR'. More preferably still, R 2 ' v is H, CN, or N0 2 .
  • X' is CH2.
  • Y is C.
  • R2 ⁇ v is CN or NO2.
  • R9 is selected from the group consisting of
  • Xi "" is selected from the group consisting of CN, NO2, Cl, F, Br, H, R, and
  • OSO2R wherein R represents ⁇ . 4 alkyl, or C3.6 cycloalkyl
  • X2"", X3"", and X4" are, independently, selected from the group consisting of CN, NO2, Cl, F, Br, H,and OS02R', provided that either X"" ⁇ or X""3 is H, wherein R' is C j _4 alkyl or haloalkyl; or Xj "" and X2"" together form an aryl or heteroaryl ring, substituted or unsubstituted; wherein the heteroatom is selected from N, S and O and the substituents are selected from the group consisting of halo, C ⁇ 4 alkyl, OCF3, CF3, OMe, CN, OS ⁇ 2-C!. 4 alkyl, OSO2-C3.6 cycloalkyl and N0 2 ; or X2"" and X4 "" independently represent C(0)Rj;
  • R9 is selected from the group consisting of 0-(CH2)n-aryl, and O- aryl;
  • Xi "" is selected from the group consisting of CN, NO2, and Cl X2"".
  • X3"". and X4"" are, independently, selected from the group consisting of Cl,
  • R9 is selected from the group consisting of 0-(CH2)n-aryl, and O- aryl; X 1 "" is CN or N ⁇ 2,
  • X 2 " " is Cl
  • X 3 "” and X 4 "" are, independently F, and H.
  • Preferred heteroaryls useful in the present invention include unsubstituted and substituted quinolines, isoquinolines, benzofurans, dihydrobenzofurans, benzothiophenes, dihydrobenzothiophenes and pyridines.
  • cycloalkyl refers to optionally substituted 3-7 membered carbocyclic rings wherein any substituents are selected from the group consisting of, F, Cl, Br, I, N(Rj)2, SRj and ORi, unless otherwise indicated.
  • heterocycloalkyl refers to optionally substituted 4, 5, 6 or 7 membered heterocyclic rings containing 1 to 2 heteroatoms selected from N, O, and S.
  • aryl refers to an optionally substituted aromatic group with at least one ring having a conjugated pi-electron system, containing up to two conjugated or fused ring systems.
  • Aryl includes carbocyclic aryl, and biaryl groups, all of which may be optionally substituted.
  • Preferred aryl include phenyl and naphthyl. More preferred aryl include phenyl.
  • Preferred substituents are selected from the group consisting of halo, Cj_4 alkyl, OCF3 CF3 OMe, CN, OS ⁇ 2 R nd N ⁇ 2 wherein R represents ⁇ alkyl or C3.6 cycloalkyl.
  • acyl refers to C1.4 alkylcarbonyl.
  • alkenyl refers to an optionally substituted hydrocarbon group containing at least one carbon-carbon double bond and containing upto 5 carbon atoms joined together.
  • the alkenyl hydrocarbon chain may be straight, branched or cyclic. Any substituents are selected from the group consisting of halo, C1..4 alkyl, OCF3 5 CF 3> OMe, CN, OSO2 R and N02, wherein R represents C ⁇ _4 alkyl or C3.6 cycloalkyl.
  • alkynyl refers to an optionally substituted hydrocarbon group containing at least one carbon-carbon triple bond between the carbon atoms and containing up to 5 carbon atoms joined together.
  • the alkynyl hydrocarbon group may be straight-chained, branched or cyclic. Any substituents are selected from the group consisting of halo, C ⁇ 4 alkyl, OCF3, CF3, OMe, CN, OSO2 R and NO2, wherein R represents C1.4 alkyl or C3.6 cycloalkyl.
  • the compounds of the present invention may contain one or more asymmetric carbon atoms and may exist in racemic and optically active forms. All of these compounds and diastereomers are contemplated to be within the scope of the present invention.
  • Preferred compounds of the present invention are selected from the group consisting of: (R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]-l,l-dimethyl-2-(2,3- dihydrobenzo[b]furan-5yl)ethylamine;
  • 2-ynylamine and pharmaceutically acceptable salts and complexes thereof.
  • Preferred salts include hydrochloride and dihydrochloride.
  • More preferred compounds useful in the present invention include: (R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]-l,l-dimethyl-2-(2,3- dihydrobenzo[b]furan-5yl)ethylamine;
  • Pharmaceutically acceptable salts are non-toxic salts in the amounts and concentrations at which they are administered.
  • Pharmaceutically acceptable salts include acid addition salts such as those containing sulfate, hydrochloride, fumarate, maleate, phosphate, sulfamate, acetate, citrate, lactate, tartrate, methanesulfonate, ethanesulfonate, benzenesulfonate, p- toluenesulfonate, cyclohexylsulfamate and quinate.
  • a preferred salt is a hydrochloride.
  • Pharmaceutically acceptable salts can be obtained from acids such as hydrochloric acid, maleic acid, sulfuric acid, phosphoric acid, sulfamic acid, acetic acid, citric acid, lactic acid, tartaric acid, malonic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, cyclohexylsulfamic acid, fumaric acid, and quinic acid.
  • acids such as hydrochloric acid, maleic acid, sulfuric acid, phosphoric acid, sulfamic acid, acetic acid, citric acid, lactic acid, tartaric acid, malonic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, cyclohexylsulfamic acid, fumaric acid, and quinic acid.
  • Pharmaceutically acceptable salts also include basic addition salts such as those containing benzathine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine, procaine, aluminum, calcium, lithium, magnesium, potassium, sodium, ammonium, alkylamine, and zinc, when acidic functional groups, such as carboxylic acid or phenol are present.
  • the present invention provides compounds of Formula (I) above, which can be prepared using standard techniques. An overall strategy for preparing preferred compounds described herein can be carried out as described in this section. The examples which follow illustrate the synthesis of specific compounds. Using the protocols described herein as a model, one of ordinary skill in the art can readily produce other compounds of the present invention.
  • Nuclear magnetic resonance spectra were recorded at either 250 or 400 MHz using, respectively, a Bruker AM 250 or Bruker AC 400 spectrometer.
  • CDCI3 is deuteriochloroform
  • DMSO-d6 is hexadeuteriodimethylsulfoxide
  • CD3OD is tetradeuteriomethanol. Chemical shifts are reported in parts per million (•) downfield from the internal standard tetramethylsilane.
  • ODS refers to an octadecylsilyl derivatized silica gel chromatographic support. 5 ⁇ Apex-ODS indicates an octadecylsilyl derivatized silica gel chromatographic support having a nominal particle size of 5 ⁇ , made by Jones Chromatography, Littleton, Colorado.
  • YMC ODS-AQ® is an ODS chromatographic support and is a registered trademark of YMC Co. Ltd., Kyoto, Japan.
  • PRP-1® is a polymeric (styrene-divinylbenzene) chromatographic support, and is a registered trademark of Hamilton Co., Reno, Nevada)
  • Celite® is a filter aid composed of acid-washed diatomaceous silica, and is a registered trademark of Manville Corp., Denver, Colorado.
  • a compound of Formula (I) or a pharmaceutically acceptable salt thereof for the treatment of humans and other mammals, it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.
  • the calcilytic compounds can be administered by different routes including intravenous, intraperitoneal, subcutaneous, intramuscular, oral, topical (transdermal), or transmucosal administration.
  • oral administration is preferred.
  • the compounds can be formulated into conventional oral dosage forms such as capsules, tablets, and liquid preparations such as syrups, elixirs, and concentrated drops.
  • injection parenteral administration
  • the compounds of the invention are formulated in liquid solutions, preferably, in physiologically compatible buffers or solutions, such as saline solution, Hank's solution, or Ringer's solution.
  • the compounds may be formulated in solid form and redissolved or suspended immediately prior to use. Lyophilized forms can also be produced.
  • Systemic administration can also be by transmucosal or transdermal means.
  • penetrants appropriate to the barrier to be permeated are used in the formulation.
  • penetrants are generally known in the art, and include, for example, for transmucosal administration, bile salts and fusidic acid derivatives.
  • detergents may be used to facilitate permeation.
  • Transmucosal administration for example, may be through nasal sprays, rectal suppositories, or vaginal suppositories.
  • the compounds of the invention can be formulated into ointments, salves, gels, or creams, as is generally known in the art.
  • the amounts of various calcilytic compounds to be administered can be determined by standard procedures taking into account factors such as the compound IC50, EC50, the biological half-life of the compound, the age, size and weight of the patient, and the disease or disorder associated with the patient. The importance of these and other factors to be considered are known to those of ordinary skill in the art.
  • Amounts administered also depend on the routes of administration and the degree of oral bioavailability. For example, for compounds with low oral bioavailability, relatively higher doses will have to be administered.
  • the composition is in unit dosage form.
  • a tablet, or capsule may be administered, for nasal application, a metered aerosol dose may be administered, for transdermal application, a topical formulation or patch may be administered and for transmucosal delivery, a buccal patch may be administered.
  • dosing is such that the patient may administer a single dose.
  • Each dosage unit for oral administration contains suitably from 0.01 to 500 mg/Kg, and preferably from 0.1 to 50 mg/Kg, of a compound of Formula (I) or a
  • the daily dosage for parenteral, nasal, oral inhalation, transmucosal or transdermal routes contains suitably from 0.01 mg to 100 mg/Kg, of a compound of Formula(I).
  • a topical formulation contains suitably 0.01 to 5.0% of a compound of Formula (I).
  • the active ingredient may be administered, for example, from 1 to 6 times per day, preferably once, sufficient to exhibit the desired activity, as is readily apparent to one skilled in the art.
  • treatment of a disease includes, but is not limited to prevention, retardation and prophylaxis of the disease.
  • Diseases and disorders which might be treated or prevented, based upon the affected cells include bone and mineral-related diseases or disorders; hypoparathyroidism; those of the central nervous system such as seizures, stroke, head trauma, spinal cord injury, hypoxia-induced nerve cell damage, such as occurs in cardiac arrest or neonatal distress, epilepsy, neurodegenerative diseases such as Alzheimer's disease, Huntington's disease and Parkinson's disease, dementia, muscle tension, depression, anxiety, panic disorder, obsessive-compulsive disorder, post-traumatic stress disorder, schizophrenia, neuroleptic malignant syndrome, and Tourette's syndrome; diseases involving excess water reabsorption by the kidney, such as syndrome of inappropriate ADH secretion (SIADH), cirrhosis, congestive heart failure, and nephrosis; hypertension; preventing and/or decreasing renal toxicity from cationic antibiotics (e.g., aminoglycoside), amino
  • the present compounds are used to increase serum parathyroid hormone ("PTH") levels.
  • PTH serum parathyroid hormone
  • Increasing serum PTH levels can be helpful in treating diseases such as hypoparathyroidism, osteosarcoma, periodontal disease, fracture, osteoarthritis, rheumatoid arthritis, Paget's disease, humoral hypercalcemia malignancy and osteoporosis.
  • Another aspect of the present invention describes a method of treating a patient comprising administering to the patient an amount of a present compound sufficient to increase the serum PTH level.
  • the method is carried out by
  • the compound administered to a patient causes an increase in serum PTH having a duration of up to one hour, about one to about twenty-four hours, about one to about twelve hours, about one to about six hours, about one to about five hours, about one to about four hours, about two to about five hours, about two to about four hours, or about three to about six hours.
  • the compound administered causes an increase in serum PTH of longer than about twenty-four hours, but the compound is co-administered with an anti-resorptive agent.
  • the compound administered to a patient causes an increase in serum PTH of up to two fold, two to five fold, five to ten fold, and at least 10 fold, greater than peak serum PTH in the patient.
  • the peak serum level is measured with respect to a patient not undergoing treatment.
  • Composition of Formula (I) and their pharmaceutically acceptable salts which are active when given orally, can be formulated as syrups, tablets, capsules and lozenges.
  • a syrup formulation will generally consist of a suspension or solution of the compound or salt in a liquid carrier for example, ethanol, peanut oil, olive oil, glycerine or water with a flavoring or coloring agent. Where the composition is in the form of a tablet, any pharmaceutical carrier routinely used for preparing solid formulations may be used.
  • any routine encapsulation is suitable, for example using the aforementioned carriers in a hard gelatin capsule shell.
  • any pharmaceutical carrier routinely used for preparing dispersions or suspensions may be considered, for example aqueous gums, celluloses, silicates or oils, and are incorporated in a soft gelatin capsule shell.
  • Typical parenteral compositions consist of a solution or suspension of a compound or salt in a sterile aqueous or non-aqueous carrier optionally containing a parenterally acceptable oil, for example polyethylene glycol, polyvinylpyrrolidone, lecithin, arachis oil or sesame oil.
  • a parenterally acceptable oil for example polyethylene glycol, polyvinylpyrrolidone, lecithin, arachis oil or sesame oil.
  • compositions for inhalation are in the form of a solution, suspension or emulsion that may be administered as a dry powder or in the form of an aerosol using a conventional propellant such as dichlorodifluoromethane or trichlorofluoromethane.
  • a typical suppository formulation comprises a compound of Formula (I) or a pharmaceutically acceptable salt thereof which is active when administered in this way, with a binding and/or lubricating agent, for example polymeric glycols, gelatins, cocoa-butter or other low melting vegetable waxes or fats or their synthetic analogs.
  • Typical dermal and transdermal formulations comprise a conventional aqueous or non-aqueous vehicle, for example a cream, ointment, lotion or paste or are in the form of a medicated plaster, patch or membrane.
  • the composition is in unit dosage form, for example a tablet, capsule or metered aerosol dose, so that the patient may administer a single dose. No unacceptable toxological effects are expected when compounds of the present invention are administered in accordance with the present invention.
  • Sulfate- and phosphate-free parathyroid cell buffer contains 20 mM Na-Hepes, pH 7.4, 126 mM NaCl, 5 mM KCl, and 1 mM MgCl 2 .
  • SPF-PCB was made up and stored at 4 °C. On the day of use, SPF-PCB was supplemented with 1 mg/mL of D-glucose and 1 mM CaCl2 and then split into two fractions. To one fraction, bovine serum albumin (BSA; fraction V, ICN) was added at 5 mg/mL (SPF-PCB+). This buffer was used for washing, loading and maintaining the cells. The BSA-free fraction was used for diluting the cells in the cuvette for measurements of fluorescence.
  • BSA bovine serum albumin
  • the pellet was resuspended in 10 mL of SPF-PCB+ containing 2.2 uM fluo-3 (Molecular Probes) and incubated at room temperature for 35 minutes.
  • test compound or vehicle as a control
  • Calcilytic compounds were detected by their ability to block, in a concentration-dependent manner, increases in the concentration of intracellular Ca + elicited by extracellular Ca2 + .
  • those compounds having lower IC50 values in the Calcium Receptor Inhibitor Assay are more preferred compounds.
  • Compounds having an IC50 greater than 50 uM were considered to be inactive.
  • Preferred compounds are those having an IC50 of lOuM or lower, more preferred compounds have an IC50 of luM, and most preferred compounds have an IC50 of 0.1 uM or lower.
  • HEK 2934.0-7 cells stably transfected with the Human Parathyroid Calcium Receptor("HuPCaR”) were scaled up in T 180 tissue culture flasks.
  • Plasma membrane is obtained by polytron homogenization or glass douncing in buffer (50mM Tris-HCl pH 7.4, ImM EDTA, 3mM MgCl2) in the presence of a protease inhibitor cocktail containing luM Leupeptin, 0.04 uM Pepstatin, and 1 mM PMSF. Aliquoted membrane was snap frozen and stored at -80°C.
  • ⁇ H labeled compound was radiolabeled to a radiospecific activity of 44Ci/mmole and was aliquoted and stored in liquid nitrogen for radiochemical stability.
  • a typical reaction mixture contains 2 nM ⁇ H compound ((R,R)-N-4 -
  • Nonspecific binding is determined by the addition of 100-fold excess of unlabeled homologous ligand, and is generally 20% of total binding.
  • the binding reaction is terminated by rapid filtration onto 1% PEI pretreated GF/C filters using a Brandel Harvestor. Filters are placed in scintillation fluid and radioactivity assessed by liquid scintillation counting.
  • 2-(4-Amino-4-methylpentyl)pyridine To 2-bromopyridine (0.948 g, 6 mmole) was added 9-(4-benzyloxycarbonylamino- 4-methylpentyl)-9-borabicyclo[3.3.1]nonane (12 mL, 5 mmole of a THF solution) in a nitrogen flushed reaction tube. To this solution was added 0.122 g (0.15 mmole) of [ 1 , 1 ' -bis(diphenylphosphino)ferrocene]dichloropalladium(II) dichloromethane complex (1:1), 1.38 g (10 mmole) of potassium carbonate, and 1.25 mL of water.
  • the reaction was stirred for 18 hours at 65 C, then poured into aqueous NaOH, and extracted with ether. The ether layer was separated, washed with brine, dried over sodium sulfate, and concentrated in vacuo.
  • the crude product was taken up in 20 mL of ethanol to which 1 g of palladium hydroxide on carbon (10%) was added. The mixture was stirred for 18 hours under a hydrogen balloon. The reaction mixture was filtered and concentrated in vacuo. The residue was taken up in aqueous HCI, and extracted with ether. The aqueous layer was separated, made basic with NaOH, and extracted with ether.
  • the reaction was stirred for 16.5 hours at 50 C, then poured into aqueous NaOH, and extracted with ether. The ether layer was separated, washed with brine, dried over sodium sulfate, and concentrated in vacuo.
  • the crude product was taken up in 10 mL of ethanol to which 0.3 g of palladium hydroxide on carbon (10%) was added. The mixture was stirred for 18 hours under a hydrogen balloon. The reaction mixture was filtered and concentrated in vacuo. The residue was taken up in aqueous HCI, and extracted with ether. The aqueous layer was separated, made basic with NaOH, and extracted with ether. The ether layer was dried over sodium sulfate, and concentrated in vacuo to give crude ethyl 2-(4-amino-4-methylpentyl)benzoate.
  • Formulations for pharmaceutical use inco ⁇ orating compounds of the present invention can be prepared in various forms and with numerous excipients. Examples of such formulations are given below.
  • a compound of Formula (I) (1 mg to 100 mg) is aerosolized from a metered dose inhaler to deliver the desired amount of drug per use.
  • Ingredients 1, 2, 3 and 4 are blended in a suitable mixer/blender. Sufficient water is added portion-wise to the blend with careful mixing after each addition until the mass is of a consistency to permit its conversion to wet granules.
  • the wet mass is converted to granules by passing it through an oscillating granulator using a No. 8 mesh (2.38 mm) screen.
  • the wet granules are then dried in an oven at 140°F (60°C) until dry.
  • the dry granules are lubricated with ingredient No. 5, and the lubricated granules are compressed on a suitable tablet press.
  • a pharmaceutical composition for parenteral administration is prepared by dissolving an appropriate amount of a compound of Formula (I) in polyethylene glycol with heating. This solution is then diluted with water for injections (to 100 ml). The solution is then rendered sterile by filtration through a 0.22 micron membrane filter and sealed in sterile containers. All publications, including but not limited to patents and patent applications cited in this specification are herein inco ⁇ orated by reference as if each individual publication were specifically and individually indicated to be inco ⁇ orated by reference as though fully set forth.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La présente invention concerne des composés et des compositions calcilytiques d'un type nouveau ainsi que leur utilisation pour le traitement de l'homéostasie minérale et osseuse anormale.
EP99917374A 1998-04-08 1999-04-08 Composes calcilytiques et leur utilisation Withdrawn EP1069901A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8108798P 1998-04-08 1998-04-08
US81087P 1998-04-08
PCT/US1999/007760 WO1999051241A1 (fr) 1998-04-08 1999-04-08 Composes calcilytiques et leur utilisation

Publications (2)

Publication Number Publication Date
EP1069901A1 true EP1069901A1 (fr) 2001-01-24
EP1069901A4 EP1069901A4 (fr) 2001-06-13

Family

ID=22162024

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99917374A Withdrawn EP1069901A4 (fr) 1998-04-08 1999-04-08 Composes calcilytiques et leur utilisation

Country Status (7)

Country Link
EP (1) EP1069901A4 (fr)
JP (1) JP2002510636A (fr)
AR (1) AR014975A1 (fr)
AU (1) AU3551399A (fr)
CA (1) CA2327188A1 (fr)
CO (1) CO5021223A1 (fr)
WO (1) WO1999051241A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2189439A2 (fr) 2003-04-23 2010-05-26 Japan Tobacco, Inc. Antagoniste CaSR

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5180628A1 (es) * 1999-07-31 2002-07-30 Smithkline Beecham Corp Compuestos calcioliticos
US20030018203A1 (en) 2002-07-17 2003-01-23 Largo Maria Amparo Calcilytic compounds
MY159417A (en) * 2000-01-24 2017-01-13 Smithkline Beecham Corp Calcilytic compounds
KR20030017642A (ko) * 2000-07-21 2003-03-03 스미스클라인 비참 코포레이션 칼실리틱 화합물
FR2812875B1 (fr) 2000-08-08 2003-12-12 Centre Nat Rech Scient Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation
US6916956B2 (en) 2000-08-11 2005-07-12 Japan Tobacco, Inc. Calcium receptor antagonist
EP1383511B1 (fr) * 2000-10-25 2006-10-25 SmithKline Beecham Corporation Composes calcilytiques
US6476046B1 (en) 2000-12-04 2002-11-05 Sepracor, Inc. Diazabicyclo[4.3.0]nonanes, and methods of use thereof
DE60335635D1 (de) 2002-05-22 2011-02-17 Amgen Inc Aminopyrimidin-derivate zur verwendung als vanilloid-rezeptor-liganden zur behandlung von schmerzen
TW200410945A (en) 2002-08-08 2004-07-01 Amgen Inc Vanilloid receptor ligands and their use in treatments"
AR042132A1 (es) 2002-11-26 2005-06-08 Smithkline Beecham Corp Compuesto de 2- hidroxi -3-(2- aril - 1, 1 - dimetiletilamino) propoxifenilo, composicion farmaceutica que lo comprende y uso del mismo para prepararla
WO2004069793A2 (fr) 2003-01-28 2004-08-19 Bristol-Myers Squibb Company Nouveaux amines cycliques substitues en position 2 comme modulateurs du recepteur de detection de calcium
US7205322B2 (en) 2003-02-12 2007-04-17 Bristol-Myers Squibb Company Thiazolidine compounds as calcium sensing receptor modulators
US7265145B2 (en) 2003-05-28 2007-09-04 Bristol-Myers Squibb Company Substituted piperidines and pyrrolidines as calcium sensing receptor modulators and method
JPWO2004106280A1 (ja) 2003-05-28 2006-07-20 日本たばこ産業株式会社 ＣａＳＲアンタゴニスト
MY139645A (en) 2004-02-11 2009-10-30 Amgen Inc Vanilloid receptor ligands and their use in treatments
JP2007522233A (ja) 2004-02-11 2007-08-09 アムジエン・インコーポレーテツド バニロイド受容体リガンド及び治療におけるそれらの使用
US7301022B2 (en) 2005-02-15 2007-11-27 Amgen Inc. Vanilloid receptor ligands and their use in treatments
WO2010103429A1 (fr) 2009-03-10 2010-09-16 Pfizer Inc. Dérivés de l'acide 1,1-(diméthyl-éthylamino)-2-hydroxy-propoxy]-éthyl}-3-méthyl-biphényl-4-carboxylique utiles en tant qu'antagonistes des récepteurs du calcium

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL83966A (en) * 1986-09-26 1992-03-29 Schering Ag Amides of aminopolycarboxylic acids and pharmaceutical compositions containing them
UY24949A1 (es) * 1997-04-08 2001-04-30 Smithkline Beecham Corp Compuestos calcilíticos

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *
See also references of WO9951241A1 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2189439A2 (fr) 2003-04-23 2010-05-26 Japan Tobacco, Inc. Antagoniste CaSR
EP2308828A2 (fr) 2003-04-23 2011-04-13 Japan Tobacco Inc. Antagoniste de CaSR

Also Published As

Publication number Publication date
EP1069901A4 (fr) 2001-06-13
CA2327188A1 (fr) 1999-10-14
AR014975A1 (es) 2001-04-11
CO5021223A1 (es) 2001-03-27
AU3551399A (en) 1999-10-25
WO1999051241A1 (fr) 1999-10-14
JP2002510636A (ja) 2002-04-09

Similar Documents

Publication Publication Date Title
WO1999051241A1 (fr) Composes calcilytiques et leur utilisation
US6335338B1 (en) Calcilytic compounds
US6417215B1 (en) Calcilytic compounds
WO2005077892A1 (fr) Composes calcilytiques
US20040009980A1 (en) Calcilytic compounds
EP1368318B1 (fr) Composes calcilytiques
EP1254106B1 (fr) Composes calcilytiques
US6864267B2 (en) Calcilytic compounds
US6291459B1 (en) Calcilytic compounds
AU2001276923A1 (en) Calcilytic compounds
EP1383511B1 (fr) Composes calcilytiques
US7109238B2 (en) Calcilytic compounds
US20020052509A1 (en) Calcilytic compounds and method of use
WO2005030746A1 (fr) Composes calcilytiques

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001030

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE ES FR GB IT LI NL

A4 Supplementary search report drawn up and despatched

Effective date: 20010426

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): BE CH DE ES FR GB IT LI NL

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/535 A, 7A 01N 43/02 B, 7A 01N 43/40 B, 7A 01N 43/42 B, 7C 07D 211/70 B, 7C 07D 211/72 B, 7C 07D 217/12 B, 7C 07D 217/16 B, 7C 07D 217/18 B, 7C 07D 307/02 B, 7C 07C 255/54 B, 7C 07D 307/79 B, 7C 07D 213/38 B, 7C 07D 215/12 B, 7C 07D 217/14 B

17Q First examination report despatched

Effective date: 20020305

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020916